Invivyd (IVVD) Change in Accured Expenses (2021 - 2025)
Invivyd's (IVVD) quarterly Change in Accured Expenses came in at -$6.0 million in Q4 2025, up 15.05% on a YoY basis from -$5.2 million in Q4 2024, and down 2296.81% quarter-over-quarter from -$251000.0 in Q3 2025.
Analysis
Invivyd (IVVD) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Change in Accured Expenses for 5 consecutive years, with -$6.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Change in Accured Expenses rose 15.05% year-over-year to -$6.0 million; the trailing twelve-month figure through Dec 2025 stood at -$30.8 million (down 444.66% YoY), and the FY2025 full-year result was -$30.8 million, down 444.66% from the prior year.
- Change in Accured Expenses declined to -$6.0 million in Q4 2025 per IVVD's latest filing, from -$251000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $31.9 million in Q3 2024 and bottomed at -$23.9 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged $687800.0 across 5 years, with a median of -$6.5 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Change in Accured Expenses slumped 375.88% in 2022, then soared 436.58% in 2023.
- Over 5 years, Change in Accured Expenses stood at $21.2 million in 2021, then plunged by 134.44% to -$7.3 million in 2022, then jumped by 436.58% to $24.6 million in 2023, then sank by 128.77% to -$7.1 million in 2024, then climbed by 15.05% to -$6.0 million in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$6.0 million, -$251000.0, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -6.02 Mn |
| Sep 30, 2025 | -251,000.00 |
| Jun 30, 2025 | -14.57 Mn |
| Mar 31, 2025 | -10.01 Mn |
| Dec 31, 2024 | -7.08 Mn |
| Sep 30, 2024 | 31.85 Mn |
| Jun 30, 2024 | -8.86 Mn |
| Mar 31, 2024 | -6.96 Mn |
| Dec 31, 2023 | 24.61 Mn |
| Sep 30, 2023 | -10.79 Mn |
| Jun 30, 2023 | 12.24 Mn |
| Mar 31, 2023 | -6.91 Mn |
| Dec 31, 2022 | -7.31 Mn |
| Sep 30, 2022 | -23.90 Mn |
| Jun 30, 2022 | -23.91 Mn |
| Mar 31, 2022 | 20.26 Mn |
| Dec 31, 2021 | 21.24 Mn |
| Sep 30, 2021 | 9.07 Mn |
| Jun 30, 2021 | 8.67 Mn |
| Mar 31, 2021 | 12.39 Mn |